If you're taking a GLP-1 medication — or thinking about starting one — there's a new piece of research you need to know about. And more importantly, there's a blind spot in how most people track their results that could be quietly costing them their muscle, their metabolism, and their long-term health.
Let's break it down.
The Headline Study: Tirzepatide Drops More Weight — But Takes More Muscle With It
A new real-world analysis released this week by U.S. data analytics firm nference tracked body composition in roughly 8,000 patients on GLP-1 therapy — about 1,800 using tirzepatide (Mounjaro, Zepbound) and 6,200 using semaglutide (Ozempic, Wegovy). The findings are significant.
On average, tirzepatide patients lost 1.1% more lean body mass at three months and 2% more at twelve months compared to those on semaglutide. The gap widened at the top end of weight loss: among patients who lost more than 20% of their body weight, roughly 1 in 10 tirzepatide users lost more than 5% of their lean body mass, versus fewer than 7% of semaglutide users achieving the same overall weight loss.
Lean body mass isn't just muscle. It includes bone, connective tissue, and organs — all the metabolically active tissue that keeps you strong, mobile, and functional as you age. Losing too much of it raises real concerns about sarcopenia, frailty, slower metabolism, and weight regain after stopping the medication.
The study's lead author, Venky Soundararajan, put it bluntly in comments to Reuters: patients shouldn't simply pick whichever drug produces the biggest number on the scale. The composition of that weight loss matters just as much — if not more.
📎 Read the original coverage: Tirzepatide linked to more lean mass loss than semaglutide — European Medical Journal
Why the Mechanism Probably Matters
Semaglutide acts on a single receptor (GLP-1). Tirzepatide is a dual agonist, hitting both GLP-1 and GIP receptors. That dual action is part of why tirzepatide tends to produce greater total weight loss — but it may also be why patients shed more lean tissue alongside the fat.
It's worth noting the picture isn't fully settled. A systematic review of tirzepatide trials published in PMC found that in controlled studies like SURMOUNT-1, roughly 75% of weight loss came from fat and 25% from lean mass — a reasonable ratio. A SURPASS-3 MRI substudy in The Lancet Diabetes & Endocrinology even showed tirzepatide improved muscle quality by reducing fat infiltration within muscle tissue.
So the drug isn't the villain. But the real-world data tells us outcomes vary a lot depending on the individual — their exercise habits, protein intake, dose, and starting condition. Soundararajan's warning was direct: if you're not exercising while on these medications, you're essentially causing attrition of lean body mass.
Which brings us to the part most patients are getting wrong.
The Scale Is Lying to You
A bathroom scale tells you one number: total body weight. It cannot tell you:
- How much of that loss was fat versus muscle
- How much visceral fat (the dangerous kind around your organs) you've reduced
- Whether your bone density is holding up under rapid weight loss
- Whether your body composition is actually improving
A patient can lose 30 pounds on a GLP-1 and feel like a success story — while having quietly lost 10 pounds of muscle and some bone density along the way. That's not a win. That's a setup for regain, frailty, and a permanently slower metabolism.
DEXA: The Only Scan That Tells You the Truth
A DEXA (Dual-Energy X-ray Absorptiometry) scan is the gold standard for body composition analysis. In about ten minutes, with minimal radiation exposure roughly equivalent to a short flight, a DEXA scan gives you:
- Total and regional fat mass — broken down by arms, legs, and trunk
- Lean muscle mass by region — so you can catch asymmetries and losses early
- Visceral adipose tissue (VAT) — the fat that actually drives cardiovascular and metabolic disease risk
- Bone mineral density — critical for anyone losing weight rapidly, especially women over 40 and anyone with a family history of osteoporosis
Unlike bioelectrical impedance scales at the gym or most consumer smart scales, DEXA doesn't estimate your composition from an algorithm guessing at how electricity moves through your body. It directly measures tissue density with X-rays. Hydration, meal timing, and skin temperature don't skew the result.
What to Do With a DEXA When You're on a GLP-1
Here's the protocol we recommend for anyone starting or currently using tirzepatide or semaglutide:
- Get a baseline scan before starting or as early as possible. You cannot measure change without a starting point.
- Rescan every 3 months during active weight loss. This cadence catches muscle loss early — while there's still time to correct it with protein and resistance training.
- Track the ratio, not just the number. The goal is for roughly 75–85% of lost weight to come from fat. If you're dropping lean mass faster than that, something in your plan needs to change.
- Watch visceral fat and bone density. These are the longevity metrics. A smaller waist that comes with declining bone density is not the outcome you want.
Where the DEXA+ Body Comp Scale Fits In
DEXA scans are precise, but you're not getting one every week. That's where a quality body composition scale belongs in your toolkit — as the daily check-in between clinical-grade scans.
The DEXA+ Body Fat Scale is built for exactly this use case. It tracks weight, body fat percentage, and lean mass trends at home, so you can spot meaningful shifts between DEXA appointments and bring that data into conversations with your provider. It's not a replacement for a DEXA scan — nothing at home is. But used alongside quarterly DEXAs, it keeps you engaged with your data daily instead of guessing for 90 days at a stretch.
The combination is what matters: DEXA for the truth, a smart scale for the trend line.
The Bottom Line
The new inference data is an important signal — not a reason to panic about tirzepatide, but a reason to stop flying blind on these medications. Whether you're on semaglutide, tirzepatide, or considering either, your total weight is the least informative metric about your health.
What actually matters:
- Are you losing fat or muscle?
- Is your visceral fat coming down?
- Is your bone density holding?
- Is your body composition improving, or just getting smaller?
A scale can't answer those questions. A DEXA scan can.
If you're on a GLP-1 — or about to start one — book a baseline DEXA scan before your next dose. It's the single best thing you can do to make sure the weight you're losing is the weight you actually want to lose.
Sources & Further Reading
- Tirzepatide linked to more lean mass loss than semaglutide — European Medical Journal
- Novo weight-loss drug may preserve lean body mass better than Lilly's, study finds — Reuters coverage
- Tirzepatide and muscle composition changes (SURPASS-3 MRI) — The Lancet Diabetes & Endocrinology
- Effects of Tirzepatide on Skeletal Muscle Mass in Adults: A Systematic Review — PMC
- Preservation of lean soft tissue during GLP-1 and GLP-1/GIP therapy — PMC case series
Ready to get scanned? Visit DEXASCAN.COM to find a location near you and order the DEXA+ Body Fat Scale to track progress between visits.
